Tubulis Appoints Christian Grøndahl as Independent Chairman to Lead Supervisory BoardCinthia Briseño2021-05-11T10:59:27+02:00May 11th, 2021|
Tubulis appoints Günter Fingerle-Rowson as Chief Medical Officer to lead the clinical development of its new generation of ADCsCinthia Briseño2021-05-07T10:58:05+02:00May 6th, 2021|
Tubulis Forms Strategic Partnership with WuXi Biologics and WuXi STA to Advance New Generation of Antibody-Drug Conjugates towards Clinical Evaluationdschumacher2021-05-06T00:21:43+02:00December 2nd, 2020|
Tubulis Raises €10.7 M Series A to Advance Development of a New Generation of Antibody-Drug Conjugatesdschumacher2020-07-21T13:00:31+02:00July 21st, 2020|
Tubulis and Glycotope announce research and feasibility agreement for the discovery of antibody drug conjugatesdschumacher2019-09-09T16:47:19+02:00September 11th, 2019|
